{
  "report_rows": [
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.475B vs. cons $1.455B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted Diluted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.02 vs. cons $1.00",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "PQI Segment Core Sales Growth (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~0.0% vs. cons ~1.5%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$4.26-$4.34 (mid ~$4.30) vs. cons $4.24 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 Core Sales Growth Guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~3.5-4.5% (mid ~4.0%) vs. cons ~3.8% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Q3 2026 Adjusted EPS Guidance",
      "prediction": "BETTER",
      "answer": "guide ~$1.03-$1.07 (mid ~$1.05) vs. cons $1.03 (Q3 2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 0.8,
  "day1_confidence": "LOW",
  "day5_residual_pct": -1.2,
  "day5_path": "FADE",
  "day5_rationale": "Stock already rallied ~24% off May lows and +2.5% the day before the print, pricing in a beat-and-raise; a modest EPS/revenue beat alongside a still-unresolved PQI packaging/color recovery and only a ~23.5% margin (flat y/y, step down from Q1's 25.1%) gives analysts room to trim out-quarter/FY27 estimates even after nominal FY26 guide raise, especially with cost-program cash charge and integration costs weighing on near-term consensus revisions\u2014classic 'buy the rumor, sell the news' fade after an already-extended run into the print.",
  "day5_confidence": "LOW"
}